handle: 20.500.12663/2182
At present, COVID-19 is raging all over the world. Many comorbidities, such as diabetes mellitus (OR = 2.67, 95% CI = 1.91–3.74) and hypertension (OR = 2.3, 95% CI = 1.76–3.00), have been shown to worsen the patient’s condition. However, whether cardio-cerebrovascular disease will affect COVID-19 remains unclear. In this meta-analysis, we collected studies from PubMed, Wed of Science and CNKI (Chinese) to July 25, which reported COVID-19 patients with and without cardio-cerebrovascular disease as well as their severity and mortality. The random-effect model meta-analysis was used to analyze them and get overall odds ratios (OR) with 95% CIs. Funnel plots and the Begg’s and Egger’s test were used to assess publication bias. Thirty-one studies with 23,632 patients were finally included in the meta-analysis. The results showed an OR of 3.004 (95% CI = 2.097–4.303) for COVID-19 severity and an OR of 5.587 (95% CI = 2.810–11.112) for COVID-19 mortality. Compared with cardiovascular disease, the subgroup analysis indicated that cerebrovascular disease was more likely to increase the severity (OR = 3.400, 95% CI = 1.569–7.368) and mortality (OR = 23.477, 95% CI = 3.050–180.735) of COVID-19. Therefore, it can be inferred that cardio-cerebrovascular disease is associated with an increase in the risk of severe illness and death among COVID-19 patients. This meta-analysis showed that cardio-cerebrovascular disease has a significant relation with severe and death outcomes of COVID-19. Nurses should pay special attention to COVID-19 patients with the cardio-cerebrovascular disease.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::f34a3060ab136d2e00f1231bc6c019b9&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::f34a3060ab136d2e00f1231bc6c019b9&type=result"></script>');
-->
</script>
handle: 20.500.12663/1950
Background: Several guidelines to guide clinical practice among esophagogastric surgeons during the COVID-19 pandemic were produced. However, none provide reflection of current service provision. This international survey aimed to clarify the changes observed in esophageal and gastric cancer management and surgery during the COVID-19 pandemic. Methods: An online survey covering key areas for esophagogastric cancer services, including staging investigations and oncological and surgical therapy before and during (at two separate time-points—24th March 2020 and 18th April 2020) the COVID-19 pandemic were developed. Results: A total of 234 respondents from 225 centers and 49 countries spanning six continents completed the first round of the online survey, of which 79% (n = 184) completed round 2. There was variation in the availability of staging investigations ranging from 26.5% for endoscopic ultrasound to 62.8% for spiral computed tomography scan. Definitive chemoradiotherapy was offered in 14.8% (adenocarcinoma) and 47.0% (squamous cell carcinoma) of respondents and significantly increased by almost three-fold and two-fold, respectively, in both round 1 and 2. There were uncertainty and heterogeneity surrounding prioritization of patients undergoing cancer resections. Of the surgeons symptomatic with COVID-19, only 40.2% (33/82) had routine access to COVID-19 polymerase chain reaction testing for staff. Of those who had testing available (n = 33), only 12.1% (4/33) had tested positive. Conclusions: These data highlight management challenges and several practice variations in caring for patients with esophagogastric cancers. Therefore, there is a need for clear consistent guidelines to be in place in the event of a further pandemic to ensure a standardized level of oncological care for patients with esophagogastric cancers.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::01d2ed6d4fe2237444b13763d6a802ec&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::01d2ed6d4fe2237444b13763d6a802ec&type=result"></script>');
-->
</script>
handle: 20.500.12663/2013
Introduction: The public health threat posed by the COVID-19 pandemic has led all levels of government to take unprecedented measures to help slow the spread of COVID-19 and thereby minimise serious illness, death and social disruption resulting from the pandemic. Difficult choices are being made in a context of considerable uncertainty, as knowledge about COVID-19 and the impact of unprecedented public health measures evolves rapidly. Examples include decisions about allocation of scarce resources, prioritization guidelines for vaccines and medical countermeasures, curtailment of individual freedoms, and closing or re-opening public spaces, schools and businesses. Recognizing the fundamental ethical nature of these choices can help decision makers identify competing values and interests, weigh relevant considerations, identify options and make well-considered and justifiable decisions.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::e438412a74f23c85dcf926693ccfa728&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::e438412a74f23c85dcf926693ccfa728&type=result"></script>');
-->
</script>
handle: 20.500.12663/797
Introduction: Conflict-induced displacement makes affected populations more vulnerable to HIV transmission. However, this vulnerability does not always necessarily translate into more HIV infections. The extent to which conflict and displacement affect HIV transmission depends upon numerouscompeting and interacting factors such as loss of livelihoods; availability of education; the type and the length of conflict; the living arrangements and conditions of internally displaced persons (IDPs), whether formal or informal settlement; the context of their new location; and access to health services, including HIV and sexual and reproductive health programs. These factors also have direct implications for HIV vulnerability. Vulnerability results from individual and societal factors that affect adversely one’s ability to exert control over one’s own health. The factors pertaining to the quality of coverage of services and programs also influence HIV vulnerability. The characteristics of the HIV epidemic, the prevalence in the local populations, the interactions with armed forces, the occurrence of sexual violence and the risk behaviours associated with the new situations conditions of IDPs directly affect the risk of HIV transmission. HIV risk is defined as the probability that a person may acquire HIV infection by, for example, unprotected sex with partners or injecting drug use with shared needles and syringes...
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::030c05b8a958a2195b715678006f1f85&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::030c05b8a958a2195b715678006f1f85&type=result"></script>');
-->
</script>
handle: 20.500.12663/1160
In the fight against coronavirus disease 2019 (COVID-19), now a worldwide pandemic, urgent identification of clinical and laboratory predictors of progression towards severe and fatal forms is urgently needed. These predictors will enable risk stratification, guide interventional studies to target patients at enhanced risk of developing severe disease and optimize allocation of limited human and technical resources in the ongoing pandemic. Moreover, identification of laboratory parameters capable of discriminating between severe and non-severe cases, or those at high or low risk of mortality, will allow for improved clinical situational awareness. Though similarities are noted between COVID-19 and the severe acute respiratory syndrome (SARS), the World Health Organization (WHO) has observed differences in the clinical picture of the diseases caused by the two viruses. We have previously described the typical laboratory changes in both children and adults with COVID-19, observing some notable differences in laboratory parameters between COVID-19 and SARS viruses. In earlier reports, we have identified procalcitonin and platelet count as potential predictors of disease severity. However, with an increased volume of COVID-19 reports now published, it has enabled a more comprehensive analysis of laboratory data that is urgently needed by the medical and scientific communities. The aim of this study was to analyze laboratory abnormalities in patients with COVID-19, in order to define which parameters can discriminate between those who are at higher risk of developing severe vs. non-severe forms of disease, as well as those who are less likely to survive.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::91780dcfbaee71671d9cd6b1ba0d19e1&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::91780dcfbaee71671d9cd6b1ba0d19e1&type=result"></script>');
-->
</script>
handle: 20.500.12663/1677
An epidemic of coronavirus disease 2019 (COVID‐19) has been spreading worldwide. With the rapid increase in the number of infections, children with COVID‐19 appear to be rising. Most research findings regarding adult cases, which are not always transferrable to children. Evidence‐based studies are still expected to formulate clinical decisions for pediatric patients. In this review, we evaluated the demographic, clinical, laboratory and imaging features from 2,597 pediatric patients of COVID‐19 that reported recently. We found that even lymphopenia was the most common lab finding in adults, it infrequently occurred in children (9.8%). Moreover, elevated creatine kinase MB isoenzyme (CK‐MB) was much more commonly observed in children (27.0%) than that in adults, suggesting that heart injury would be more likely to happen in pediatric patients. Our analysis may contribute to determine the spectrum of disease in children, as well as to develop strategies to control the disease transmission.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::c190fc88742bc6eb6a589cd853d7d71c&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::c190fc88742bc6eb6a589cd853d7d71c&type=result"></script>');
-->
</script>
handle: 20.500.12663/2565
OBJECTIVE: This review was conducted to systematically analyze the effects of aerobic exercise on immunological biomarkers to provide safe aerobic exercise recommendations and specifications for patients with COVID-19. MATERIALS AND METHODS: A systematic search was conducted through MEDLINE (PubMed), Science Direct, Web of Science, Scopus, Cochrane Library, and SciELO databases. The search included the following keywords “immune system”, “immune cell”, or “immune function”; “aerobic training”, “aerobic exercise”, or “physical activity”; “human” or “adult”; and “cytokine”, “killer cell”, “T cell”, “interleukin”, “lymphocyte”, “leukocyte” or “adhesion molecule”. RESULTS: Eleven studies met the inclusion and exclusion criteria of this search. The most used exercise prescriptions included walking, cycling, or running. The duration of exercise ranged from 18 to 60 min with an intensity of 55% to 80% of VO2max or 60%-80% of maximum heart rate. The frequency range was 1 to 3 times/week. The mainly increased immunological biomarkers included leukocytes, lymphocytes, neutrophils, monocytes, eosinophils, IL-6, CD16-56, CD16, CD4, CD3, CD8, and CD19. CONCLUSIONS: This review demonstrated that patients with COVID-19 should follow a regular program of aerobic exercise for 20-60 min. This program should be in the form of cycling or walking with an intensity of 55%-80% VO2max or 60%-80% of maximum heart rate. This program should be repeated 2-3 sessions/week. These previous parameters could safely enhance immune functions without producing any exhaustion.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::652a5708ff1c7c46d051e971ba0abc29&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::652a5708ff1c7c46d051e971ba0abc29&type=result"></script>');
-->
</script>
handle: 20.500.12663/2037
The Covid 19 epidemic has modified the way that plastic surgeons can treat their patients. At our hospital all elective surgery was canceled and only the more severe cases were admitted. The outpatient department activity has been reduced also. We present the number and diagnoses of patients, treated as in- and out-patients, during seven weeks from the onset of the epidemic, comparing our activity from the lockdown of elective surgery with the numbers and diagnoses observed during the same weeks of last year. Finally we underline the importance of using telemedicine and web-based tools to transmit images of lesions that need the surgeon’s evaluation, and can be used by the patient to keep in touch with a doctor during the distressing time of delay of the expected procedure.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::bb0d5eeb7ce68e19f84afae21c22d7be&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::bb0d5eeb7ce68e19f84afae21c22d7be&type=result"></script>');
-->
</script>
handle: 20.500.12663/1323
Background: Three clusters of coronavirus disease 2019 (COVID-19) linked to a tour group from China, a company conference, and a church were identified in Singapore in February, 2020. Methods: We gathered epidemiological and clinical data from individuals with confirmed COVID-19, via interviews and inpatient medical records, and we did field investigations to assess interactions and possible modes of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Open source reports were obtained for overseas cases. We reported the median (IQR) incubation period of SARS-CoV-2. Findings: As of Feb 15, 2020, 36 cases of COVID-19 were linked epidemiologically to the first three clusters of circum- scribed local transmission in Singapore. 425 close contacts were quarantined. Direct or prolonged close contact was reported among affected individuals, although indirect transmission (eg, via fomites and shared food) could not be excluded. The median incubation period of SARS-CoV-2 was 4 days (IQR 3–6). The serial interval between transmission pairs ranged between 3 days and 8 days. Interpretation: SARS-CoV-2 is transmissible in community settings, and local clusters of COVID-19 are expected in countries with high travel volume from China before the lockdown of Wuhan and institution of travel restrictions. Enhanced surveillance and contact tracing is essential to minimise the risk of widespread transmission in the community.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::88038024d3da8bb9c5adfda374e3137c&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::88038024d3da8bb9c5adfda374e3137c&type=result"></script>');
-->
</script>
handle: 20.500.12663/864
BACKGROUND Person to person spread of COIVD-19 in the UK has now been confirmed. There are limited case series reporting the impact on women affected by coronaviruses (CoV) during pregnancy. In women affected by SARS and MERS, the case fatality rate appeared higher in women affected in pregnancy compared with non-pregnant women. We conducted a rapid, review to guide management of women affected by COVID -19 during pregnancy and developed interim practice guidance with the RCOG and RCPCH to inform maternity and neonatal service planning METHODS Searches were conducted in PubMed and MedRxiv to identify primary case reports, case series, observational studies or randomised-controlled trial describing women affected by coronavirus in pregnancy and on neonates. Data was extracted from relevant papers and the review was drafted with representatives of the RCPCH and RCOG who also provided expert consensus on areas where data were lacking...
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=dedup_wf_002::060a70cb02587ece82310ae9a01ab18e&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=dedup_wf_002::060a70cb02587ece82310ae9a01ab18e&type=result"></script>');
-->
</script>
handle: 20.500.12663/2182
At present, COVID-19 is raging all over the world. Many comorbidities, such as diabetes mellitus (OR = 2.67, 95% CI = 1.91–3.74) and hypertension (OR = 2.3, 95% CI = 1.76–3.00), have been shown to worsen the patient’s condition. However, whether cardio-cerebrovascular disease will affect COVID-19 remains unclear. In this meta-analysis, we collected studies from PubMed, Wed of Science and CNKI (Chinese) to July 25, which reported COVID-19 patients with and without cardio-cerebrovascular disease as well as their severity and mortality. The random-effect model meta-analysis was used to analyze them and get overall odds ratios (OR) with 95% CIs. Funnel plots and the Begg’s and Egger’s test were used to assess publication bias. Thirty-one studies with 23,632 patients were finally included in the meta-analysis. The results showed an OR of 3.004 (95% CI = 2.097–4.303) for COVID-19 severity and an OR of 5.587 (95% CI = 2.810–11.112) for COVID-19 mortality. Compared with cardiovascular disease, the subgroup analysis indicated that cerebrovascular disease was more likely to increase the severity (OR = 3.400, 95% CI = 1.569–7.368) and mortality (OR = 23.477, 95% CI = 3.050–180.735) of COVID-19. Therefore, it can be inferred that cardio-cerebrovascular disease is associated with an increase in the risk of severe illness and death among COVID-19 patients. This meta-analysis showed that cardio-cerebrovascular disease has a significant relation with severe and death outcomes of COVID-19. Nurses should pay special attention to COVID-19 patients with the cardio-cerebrovascular disease.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::f34a3060ab136d2e00f1231bc6c019b9&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::f34a3060ab136d2e00f1231bc6c019b9&type=result"></script>');
-->
</script>
handle: 20.500.12663/1950
Background: Several guidelines to guide clinical practice among esophagogastric surgeons during the COVID-19 pandemic were produced. However, none provide reflection of current service provision. This international survey aimed to clarify the changes observed in esophageal and gastric cancer management and surgery during the COVID-19 pandemic. Methods: An online survey covering key areas for esophagogastric cancer services, including staging investigations and oncological and surgical therapy before and during (at two separate time-points—24th March 2020 and 18th April 2020) the COVID-19 pandemic were developed. Results: A total of 234 respondents from 225 centers and 49 countries spanning six continents completed the first round of the online survey, of which 79% (n = 184) completed round 2. There was variation in the availability of staging investigations ranging from 26.5% for endoscopic ultrasound to 62.8% for spiral computed tomography scan. Definitive chemoradiotherapy was offered in 14.8% (adenocarcinoma) and 47.0% (squamous cell carcinoma) of respondents and significantly increased by almost three-fold and two-fold, respectively, in both round 1 and 2. There were uncertainty and heterogeneity surrounding prioritization of patients undergoing cancer resections. Of the surgeons symptomatic with COVID-19, only 40.2% (33/82) had routine access to COVID-19 polymerase chain reaction testing for staff. Of those who had testing available (n = 33), only 12.1% (4/33) had tested positive. Conclusions: These data highlight management challenges and several practice variations in caring for patients with esophagogastric cancers. Therefore, there is a need for clear consistent guidelines to be in place in the event of a further pandemic to ensure a standardized level of oncological care for patients with esophagogastric cancers.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::01d2ed6d4fe2237444b13763d6a802ec&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::01d2ed6d4fe2237444b13763d6a802ec&type=result"></script>');
-->
</script>
handle: 20.500.12663/2013
Introduction: The public health threat posed by the COVID-19 pandemic has led all levels of government to take unprecedented measures to help slow the spread of COVID-19 and thereby minimise serious illness, death and social disruption resulting from the pandemic. Difficult choices are being made in a context of considerable uncertainty, as knowledge about COVID-19 and the impact of unprecedented public health measures evolves rapidly. Examples include decisions about allocation of scarce resources, prioritization guidelines for vaccines and medical countermeasures, curtailment of individual freedoms, and closing or re-opening public spaces, schools and businesses. Recognizing the fundamental ethical nature of these choices can help decision makers identify competing values and interests, weigh relevant considerations, identify options and make well-considered and justifiable decisions.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::e438412a74f23c85dcf926693ccfa728&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::e438412a74f23c85dcf926693ccfa728&type=result"></script>');
-->
</script>
handle: 20.500.12663/797
Introduction: Conflict-induced displacement makes affected populations more vulnerable to HIV transmission. However, this vulnerability does not always necessarily translate into more HIV infections. The extent to which conflict and displacement affect HIV transmission depends upon numerouscompeting and interacting factors such as loss of livelihoods; availability of education; the type and the length of conflict; the living arrangements and conditions of internally displaced persons (IDPs), whether formal or informal settlement; the context of their new location; and access to health services, including HIV and sexual and reproductive health programs. These factors also have direct implications for HIV vulnerability. Vulnerability results from individual and societal factors that affect adversely one’s ability to exert control over one’s own health. The factors pertaining to the quality of coverage of services and programs also influence HIV vulnerability. The characteristics of the HIV epidemic, the prevalence in the local populations, the interactions with armed forces, the occurrence of sexual violence and the risk behaviours associated with the new situations conditions of IDPs directly affect the risk of HIV transmission. HIV risk is defined as the probability that a person may acquire HIV infection by, for example, unprotected sex with partners or injecting drug use with shared needles and syringes...
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::030c05b8a958a2195b715678006f1f85&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::030c05b8a958a2195b715678006f1f85&type=result"></script>');
-->
</script>
handle: 20.500.12663/1160
In the fight against coronavirus disease 2019 (COVID-19), now a worldwide pandemic, urgent identification of clinical and laboratory predictors of progression towards severe and fatal forms is urgently needed. These predictors will enable risk stratification, guide interventional studies to target patients at enhanced risk of developing severe disease and optimize allocation of limited human and technical resources in the ongoing pandemic. Moreover, identification of laboratory parameters capable of discriminating between severe and non-severe cases, or those at high or low risk of mortality, will allow for improved clinical situational awareness. Though similarities are noted between COVID-19 and the severe acute respiratory syndrome (SARS), the World Health Organization (WHO) has observed differences in the clinical picture of the diseases caused by the two viruses. We have previously described the typical laboratory changes in both children and adults with COVID-19, observing some notable differences in laboratory parameters between COVID-19 and SARS viruses. In earlier reports, we have identified procalcitonin and platelet count as potential predictors of disease severity. However, with an increased volume of COVID-19 reports now published, it has enabled a more comprehensive analysis of laboratory data that is urgently needed by the medical and scientific communities. The aim of this study was to analyze laboratory abnormalities in patients with COVID-19, in order to define which parameters can discriminate between those who are at higher risk of developing severe vs. non-severe forms of disease, as well as those who are less likely to survive.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::91780dcfbaee71671d9cd6b1ba0d19e1&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::91780dcfbaee71671d9cd6b1ba0d19e1&type=result"></script>');
-->
</script>
handle: 20.500.12663/1677
An epidemic of coronavirus disease 2019 (COVID‐19) has been spreading worldwide. With the rapid increase in the number of infections, children with COVID‐19 appear to be rising. Most research findings regarding adult cases, which are not always transferrable to children. Evidence‐based studies are still expected to formulate clinical decisions for pediatric patients. In this review, we evaluated the demographic, clinical, laboratory and imaging features from 2,597 pediatric patients of COVID‐19 that reported recently. We found that even lymphopenia was the most common lab finding in adults, it infrequently occurred in children (9.8%). Moreover, elevated creatine kinase MB isoenzyme (CK‐MB) was much more commonly observed in children (27.0%) than that in adults, suggesting that heart injury would be more likely to happen in pediatric patients. Our analysis may contribute to determine the spectrum of disease in children, as well as to develop strategies to control the disease transmission.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::c190fc88742bc6eb6a589cd853d7d71c&type=result"></script>');
-->
</script>
citations | 0 | |
popularity | Average | |
influence | Average | |
impulse | Average |
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=paho_covid19::c190fc88742bc6eb6a589cd853d7d71c&type=result"></script>');
-->
</script>
handle: 20.500.12663/2565
OBJECTIVE: This review was conducted to systematically analyze the effects of aerobic exercise on immunological biomarkers to provide safe aerobic exercise recommendations and specifications for patients with COVID-19. MATERIALS AND METHODS: A systematic search was conducted through MEDLINE (PubMed), Science Direct, Web of Science, Scopus, Cochrane Library, and SciELO databases. The search included the following keywords “immune system”, “immune cell”, or “immune function”; “aerobic training”, “aerobic exercise”, or “physical activity”; “human” or “adult”; and “cytokine”, “killer cell”, “T cell”, “interleukin”, “lymphocyte”, “leukocyte” or “adhesion molecule”. RESULTS: Eleven studies met the inclusion and exclusion criteria of this search. The most used exercise prescriptions included walking, cycling, or running. The duration of exercise ranged from 18 to 60 min with an intensity of 55% to 80% of VO2max or 60%-80% of maximum heart rate. The frequency range was 1 to 3 times/week. The mainly increased immunological biomarkers included leukocytes, lymphocytes, neutrophils, monocytes, eosinophils, IL-6, CD16-56, CD16, CD4, CD3, CD8, and CD19. CONCLUSIONS: This review demonstrated that patients with COVID-19 should follow a regular program of aerobic exercise for 20-60 min. This program should be in the form of cycling or walking with an intensity of 55%-80% VO2max or 60%-80% of maximum heart rate. This program should be repeated 2-3 sessions/week. These previous parameters could safely enhance immune functions without producing any exhaustion.